Form 4: KalVista Director Granted 30,000 Stock Options

KalVista Pharmaceuticals Director Edward W. Unkart was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

Summary

• Edward W. Unkart, a Director of KalVista Pharmaceuticals, Inc. (KALV), was granted 30,000 stock options.
• The options have an exercise price of $12.05 per share.
• The grant date for these options was October 1, 2025.
• The options vest over a 12-month period, with 1/12th vesting on November 1, 2025, and subsequent 1/12th portions vesting monthly thereafter, contingent on continued service.
• The expiration date for these stock options is September 30, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grant of options to a director is a standard compensation practice that aligns interests, which is generally viewed favorably. There are no negative implications from this specific filing.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The establishment of a Rule 10b5-1 plan demonstrates a structured approach to insider trading compliance.

Management Comments

• Director Edward W. Unkart received a grant of 30,000 stock options.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to attract and retain talent while aligning leadership incentives with shareholder value creation. The use of Rule 10b5-1 plans is standard practice for insiders to manage their equity holdings in compliance with SEC regulations.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across many industries, including biotech, to incentivize long-term performance and align interests with shareholders.
• The vesting schedule of 12 months is relatively short compared to typical multi-year vesting schedules (e.g., 3-4 years) often seen for executive grants, though it can be common for director annual grants.
• The exercise price being at or above the market price on the grant date (implied by the lack of a discount) is a standard practice for incentive stock options.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director can align management incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees mentioned in this filing.

Next Steps

• The stock options will begin vesting on November 1, 2025, with monthly vesting thereafter, subject to continued service.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Rule 10b5-1